In these patients, no difference in IPT-weighted cumulative incidence was observed in metastatic disease at diagnosis in the factor Xa inhibitor group (432/23,711; 1.86%, 95% CI [1.61%,2.16%]) and the dabigatran group (414/23,715; 1.79%, 95% CI [1.56%,2.05%]; SHR 1.04, 95% CI [0.91,1.19]). This evidence concerns the gene F10 and metastatic neoplasm.